PriceTargets.com logo

Summit Therapeutics - SMMT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $33.33
  • Forecasted Upside: 86.53%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$17.87 As of 12/20/2024 06:40 PM ET
▼ -0.53 (-2.88%)

This chart shows the closing price for SMMT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Summit Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SMMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SMMT

Analyst Price Target is $33.33
▲ +86.53% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $33.33, with a high forecast of $44.00 and a low forecast of $23.00. The average price target represents a 86.53% upside from the last price of $17.87.

This chart shows the closing price for SMMT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in Summit Therapeutics. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/11/2024Wells Fargo & CompanyInitiated CoverageOverweight$30.00
12/6/2024Jefferies Financial GroupInitiated CoverageBuy$31.00
11/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$44.00 ➝ $44.00
11/4/2024JMP SecuritiesInitiated CoverageMarket Outperform$32.00
10/31/2024HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $44.00
10/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
9/27/2024CitigroupDowngradeBuy ➝ Neutral$19.00 ➝ $23.00
9/25/2024Stifel NicolausBoost TargetBuy ➝ Buy$25.00 ➝ $40.00
9/16/2024HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $45.00
9/9/2024CitigroupBoost TargetBuy ➝ Buy$13.00 ➝ $19.00
9/9/2024Stifel NicolausBoost TargetBuy ➝ Buy$14.00 ➝ $25.00
9/9/2024HC WainwrightBoost TargetBuy ➝ Buy$16.00 ➝ $30.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
8/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
8/12/2024HC WainwrightInitiated CoverageBuy ➝ Buy$16.00 ➝ $16.00
6/3/2024Stifel NicolausBoost TargetBuy ➝ Buy$8.00 ➝ $14.00
5/31/2024CitigroupBoost TargetBuy ➝ Buy$7.00 ➝ $13.00
5/7/2024CitigroupInitiated CoverageBuy$7.00
3/26/2024Stifel NicolausInitiated CoverageBuy$8.00
12/6/2021HC WainwrightReiterated RatingHold
11/18/2020HC WainwrightDowngradeBuy ➝ Neutral
5/1/2020HC WainwrightReiterated RatingBuy$4.00
3/19/2020HC WainwrightInitiated CoverageBuy$4.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 5 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 5 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 18 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 19 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 13 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 18 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 18 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Summit Therapeutics logo
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $17.87
Low: $17.71
High: $18.60

50 Day Range

MA: $19.51
Low: $16.98
High: $23.46

52 Week Range

Now: $17.87
Low: $2.10
High: $33.89

Volume

7,096,417 shs

Average Volume

3,443,122 shs

Market Capitalization

$13.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Summit Therapeutics?

The following Wall Street analysts have issued reports on Summit Therapeutics in the last year: Citigroup Inc., HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Stifel Nicolaus, and Wells Fargo & Company.
View the latest analyst ratings for SMMT.

What is the current price target for Summit Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Summit Therapeutics in the last year. Their average twelve-month price target is $33.33, suggesting a possible upside of 86.5%. HC Wainwright has the highest price target set, predicting SMMT will reach $44.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $23.00 for Summit Therapeutics in the next year.
View the latest price targets for SMMT.

What is the current consensus analyst rating for Summit Therapeutics?

Summit Therapeutics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SMMT.

What other companies compete with Summit Therapeutics?

Other companies that are similar to Summit Therapeutics include Takeda Pharmaceutical, BioNTech, Teva Pharmaceutical Industries, BeiGene and Moderna. Learn More about companies similar to Summit Therapeutics.

How do I contact Summit Therapeutics' investor relations team?

Summit Therapeutics' physical mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company's listed phone number is 650-460-8308 and its investor relations email address is [email protected]. The official website for Summit Therapeutics is www.summitplc.com. Learn More about contacing Summit Therapeutics investor relations.